HEALTH PROFESSIONAL · SOURCE READING

Clofarabine

Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: January 6, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Childhood LCH / Recurrent, Refractory, or Progressive Childhood LCH / Treatment of recurrent, refractory, or progressive high-risk disease: multisystem LCH / Chemotherapy

Patients who did not respond to treatment with cladribine were reported to respond to treatment with clofarabine.[146]; [147][Level of evidence C2]

Source links and citations

Evidence (clofarabine):

Eleven patients with recurrent multisystem high-risk and low-risk disease were treated with clofarabine.[141]

Source links and citations

Eleven patients with recurrent multisystem high-risk and low-risk disease were treated with clofarabine.[141]

The OS rate was 90%.

Eleven patients with recurrent multisystem high-risk and low-risk disease were treated with clofarabine.[141]

If confirmed in prospective trials, the reduced toxicity of this regimen compared with the cladribine/cytarabine combination could be advantageous, despite the cost of the drug.

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice